Sign in
Taking people in South KoreaPhase 3

Tegoprazan to protect the stomach in stroke patients taking antiplatelet medicine

Tests tegoprazan against placebo for stomach problems in people on antiplatelet therapy after stroke.

Key facts

Who runs it
Hanyang University Guri Hospital
Where
Anyang-si, Busan, Cheongju-si, Chuncheon, Daegu, Guri-si, Gwangju, Iksan, Jeonju, Seoul, and Ulsan, South KoreaSee the 24 sites
Trial code
Registry title
Tegoprazan for Prevention of Gastrointestinal Complication in Ischemic Stroke Patients on Antiplatelet Therapy (TegoStroke)
Status
Recruiting
Phase
Phase 3
People taking part
1,524 people, planned
Started
26 Jan 2026
Expected to end
Dec 2027
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Tegoprazan 50 mg
  • Placebo
Record updated
8 July 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults who have just started antiplatelet medicine after an ischemic stroke or a transient ischemic attack (TIA). It tests whether tegoprazan protects the stomach and gut.

Age
19 years or older
Sex
All sexes can join
Disease stage
Hospitalized for acute ischemic stroke or transient ischemic attack. Antiplatelet therapy started for the first time, expected to continue for at least 6 months, and within 4 weeks of the first dose at randomization.
Earlier treatment
Cannot have used a P-CAB, PPI or H2-receptor antagonist within 1 week before randomization. Antiplatelet therapy must have been started for the first time.

Main reasons for not taking part

  • Stomach ulcer diagnosis or gastrointestinal bleeding within the past year
  • Need for blood thinners (anticoagulants) at the same time
  • Expected difficulty having a gastrointestinal endoscopy during the study
  • Allergy or contraindication to a P-CAB or to benzimidazoles
  • AST, ALT, ALP or γ-GT 5 times the upper limit of normal or higher, or total bilirubin 3 times the upper limit of normal or higher

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • Age 19 years or older
  • Hospitalization for acute ischemic stroke or transient ischemic attack, with antiplatelet therapy initiated for the first time, expected to continue for at least 6 months at the treating physician's discretion per relevant stroke guidelines, and within 4 weeks of the first antiplatelet dose at the time of randomization
  • Written informed consent provided by the participant or a legally authorized representative
  • Ability and willingness to understand the study procedures described in the consent form and to comply with the study protocol

Who cannot take part

  • Need for concomitant anticoagulant therapy (transient anticoagulation such as argatroban during the index admission is permitted, with randomization after it is stopped)
  • Use of a P-CAB, PPI, or H2-receptor antagonist within 1 week before randomization, or an active indication for these agents, a mucosal protectant, or an antacid at enrollment. Temporary use of these agents during acute care in the index admission, since discontinued and without a current indication, is not exclusionary
  • Participation within the past 12 months in any of the following: (1) a clinical study that may affect the efficacy or safety assessments of the present study; (2) a study involving an investigational product or procedure not administered under standard-of-care guidelines; (3) a study that may pose additional risk to the participant. (Participation in other clinical studies is otherwise permitted.)
  • Current use of, or use within five half-lives of, a contraindicated interacting drug (atazanavir, nelfinavir, rilpivirine, and preparations containing these components)
  • History of peptic ulcer disease diagnosis or gastrointestinal bleeding within the past year. At screening, the history and findings of any EGD performed within the preceding 2 years were obtained by participant interview
  • Hypersensitivity or contraindication to a P-CAB or to benzimidazoles
  • Any other condition deemed by the investigators to render the patient unsuitable for study participation, including but not limited to:
  • AST, ALT, ALP, or γ-GT ≥5 times the upper limit of normal (ULN), or total bilirubin ≥3 times the ULN at screening
  • Anticipated difficulty in undergoing gastrointestinal endoscopy during the study period

Where in South Korea

  • Hallym University Sacred Heart HospitalAnyang-si, South KoreaContact: Seong-Ho Koh, MD, PhDTaking people
  • Dong-A University HospitalBusan, South KoreaContact: Seong-Ho Koh, MD, PhDTaking people
  • Pusan National University HospitalBusan, South KoreaContact: Seong-Ho Koh, MD, PhDTaking people
  • Chungbuk National University HospitalCheongju-si, South KoreaContact: Seong-Ho Koh, MD, PhDTaking people
  • Hallym University Chuncheon Sacred Heart HospitalChuncheon, South KoreaContact: Seong-Ho Koh, MD, PhDTaking people
  • Kangwon National University HospitalChuncheon, South KoreaContact: Seong-Ho Koh, MD, PhDTaking people
  • Keimyung University Dongsan HospitalDaegu, South KoreaContact: Seong-Ho Koh, MD, PhDTaking people
  • Kyungpook National University Chilgok HospitalDaegu, South KoreaContact: Seong-Ho Koh, MD, PhDTaking people
  • Yeungnam University Medical CenterDaegu, South KoreaContact: Seong-Ho Koh, MD, PhDTaking people
  • Hanyang University Guri HospitalGuri-si, South KoreaContact: Seong-Ho Koh, MD, PhDTaking people
  • Chonnam National University HospitalGwangju, South KoreaContact: Seong-Ho Koh, MD, PhDTaking people
  • Wonkwang University HospitalIksan, South KoreaContact: Seong-Ho Koh, MD, PhDTaking people
  • jeonbuk National University HospitalJeonju, South KoreaContact: Seong-Ho Koh, MD, PhDTaking people
  • Asan Medical CenterSeoul, South KoreaContact: Seong-Ho Koh, MD, PhDTaking people
  • Ewha Womans University Seoul HospitalSeoul, South KoreaContact: Seong-Ho Koh, MD, PhDTaking people
  • Gangnam Severance HospitalSeoul, South KoreaContact: Seong-Ho Koh, MD, PhDTaking people
  • Hanyang University HospitalSeoul, South KoreaContact: Seong-Ho Koh, MD, PhDTaking people
  • Kangdong Sacred Heart HospitalSeoul, South KoreaContact: Seong-Ho Koh, MD, PhDTaking people
  • Korea University Anam HospitalSeoul, South KoreaContact: Seong-Ho Koh, MD, PhDTaking people
  • Korea University Ansan HospitalSeoul, South KoreaContact: Seong-Ho Koh, MD, PhDTaking people
  • Kyung Hee University HospitalSeoul, South KoreaContact: Seong-Ho Koh, MD, PhDTaking people
  • Seoul Metropolitan Government Seoul National University Boramae Medical CenterSeoul, South KoreaContact: Seong-Ho Koh, MD, PhDTaking people
  • Seoul National University HospitalSeoul, South KoreaContact: Seong-Ho Koh, MD, PhDTaking people
  • Ulsan University HospitalUlsan, South KoreaContact: Seong-Ho Koh, MD, PhDTaking people

About the trial

What the trial wants to find out

Patients with ischemic stroke commonly receive antiplatelet therapy, frequently starting as dual antiplatelet therapy, which is associated with an increased risk of gastrointestinal complications. Although evidence for gastroprotection is established in coronary artery disease, no comparable guidance or evidence exists for stroke care. Tegoprazan is a potassium-competitive acid blocker offering rapid, meal-independent acid suppression with fewer drug interactions than proton pump inhibitors, yet whether it prevents such complications after stroke remains unknown. Thus, the investigators aim to evaluate whether tegoprazan reduces gastrointestinal complications in patients receiving antiplatelet therapy after ischemic stroke.

Read full original descriptionShow less

TegoStroke is a phase 3, multicenter, randomized, double-blind, placebo-controlled, superiority trial conducted at more than 20 centers in the Republic of Korea. Adult patients who are starting antiplatelet therapy after acute ischemic stroke or transient ischemic attack, and who are expected to continue it for at least 6 months, will be included. Eligible patients will be 1:1 randomized to receive oral tegoprazan 50 mg once daily or matching placebo for 180 days. The primary outcome is a composite of upper or indeterminate-origin gastrointestinal bleeding, gastric or duodenal ulcer ≥3 mm, or erosive esophagitis, ascertained up to a day-180 esophagogastroduodenoscopy. This study would provide the first randomized evidence on routine gastroprotection for patients on antiplatelet therapy after ischemic stroke.

The 2 groups in the trial

  • PlaceboPlacebo, for comparison

    Placebo + Antiplatelet therapy

  • TegoprazanTreatment being tested

    Tegoprazan 50mg daily + Antiplatelet therapy

    Treatment: Tegoprazan 50 mg

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter, Superiority, Investigator-initiated Trial of Tegoprazan for Prevention of Gastrointestinal Complication in Ischemic Stroke Patients on Antiplatelet Therapy (TegoStroke)
Plain-language title
Tegoprazan to protect the stomach in stroke patients taking antiplatelet medicineGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
8 July 2026